89bio

ETNB

Market cap $1.19B

Overview Fund Activity

8.02 USD

-0.05

0.62%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

7.93

-0.09

1.12%

1 day

-0.62%

5 days

-6.96%

1 month

-13.11%

3 months

-20.2%

6 months

-7.82%

Year to date

0.5%

1 year

-2.31%

5 years

-73.65%

10 years

-61.44%

About: 89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Employees: 93

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

43% more repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 56

39% more capital invested

Capital invested by funds: $1.14B [Q1] → $1.58B (+$444M) [Q2]

33% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]

4.7% more ownership

Funds ownership: 105.72% [Q1] → 110.42% (+4.7%) [Q2]

9% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 33

2% less funds holding

Funds holding: 186 [Q1] → 183 (-3) [Q2]

79% less call options, than puts

Call options by funds: $3.66M | Put options by funds: $17.4M

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$11

37% upside

Avg. target

$24

199% upside

High target

$32

299% upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

HC Wainwright & Co. Andrew S. Fein	$32	Buy Assumed	4 Sep 2025
B of A Securities Alexandria Hammond	$29	Buy Maintained	25 Aug 2025
RBC Capital Brian Abrahams	$11	Sector Perform Maintained	8 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ETNB published over the past 30 days

89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)

89bio, Inc. (NASDAQ:ETNB ) Cantor Global Healthcare Conference 2025 September 4, 2025 11:30 AM EDT Company Participants Rohan Palekar - CEO & Director Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Presentation Steven Seedhouse MD & Biotechnology Analyst Well, welcome, everyone, and it's really a privilege for me to introduce our next participating company at the Cantor Global Healthcare Conference. First time Steve Seedhouse from the biotech team.

89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 64,750 shares of the Company's common stock to three new employees (the “Inducement Grants”) on September 1, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio, Inc. (ETNB) Presents At Citi's Biopharma Back To School Conference Transcript

89bio, Inc. (NASDAQ:ETNB ) Citi's Biopharma Back to School Conference September 3, 2025 11:15 AM EDT Company Participants Rohan Palekar - CEO & Director Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Presentation Geoffrey Meacham Managing Director So welcome to the next session of the Citi Biopharma back-to-school event. So my name is Geoff Meacham.

89bio, Inc. (ETNB) Presents At Citi's Biopharma Back To School Conference Transcript

89bio to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's management will participate in the following investor conferences during the month of September:

89bio to Participate in Upcoming Investor Conferences

89bio: Promising As Pegozafermin Nears Phase 3 Readout

Pegozafermin is ETNB's long-acting FGF21 analog. It's undergoing three Phase 3 trials. Two of those late-stage trials are for MASH (F2-F4), and the third is for severe hypertriglyceridemia. Also, ETNB's ENTRUST SHTG is fully enrolled, with potential topline data by 1Q 2026, which may enable a BLA filing shortly after that.

89bio: Promising As Pegozafermin Nears Phase 3 Readout

The Motley Fool

89bio (ETNB) Q2 R&D Jumps 131%

89bio (ETNB) Q2 R&D Jumps 131%

89bio (ETNB) Q2 R&D Jumps 131%

89bio Reports Second Quarter 2025 Financial Results and Corporate Updates

– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – ENTRUST Phase 3 topline data in severe hypertriglyceridemia (SHTG) expected in 1Q 2026 – – Cash, cash equivalents, and marketable securities totaled $561.2 million as of June 30, 2025 – SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the second quarter ended June 30, 2025, and provided corporate updates. “As we enter the second half of 2025, we remain diligently focused on execution across our three global Phase 3 trials for pegozafermin in MASH and SHTG.

89bio Reports Second Quarter 2025 Financial Results and Corporate Updates

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 267,000 shares of the Company's common stock to three new employees (the “Inducement Grants”) on August 1, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 32,350 shares of the Company's common stock to two new employees (the “Inducement Grants”) on July 2, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 61,100 shares of the Company's common stock to three new employees (the “Inducement Grants”) on June 3, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

See News Rankings

Charts implemented using Lightweight Charts™